多部门运用追溯码查处倒卖“回流药”等问题

Core Viewpoint - The National Healthcare Security Administration (NHSA) is conducting a nationwide special rectification of prominent issues in medical insurance fund management, focusing on the abnormal tracking codes of drugs and the illegal resale of "returned drugs" by designated medical institutions [1] Group 1: Regulatory Actions - The NHSA, in collaboration with the Supreme People's Court, the Supreme People's Procuratorate, and the Ministry of Public Security, is implementing comprehensive inspections of designated medical institutions suspected of selling "returned drugs" [1] - Starting from July 1 of this year, designated medical institutions are required to scan tracking codes during the sales process before settling medical insurance funds [1] - The NHSA emphasizes the importance of using drug tracking codes and will work with relevant departments to rigorously combat the resale of "returned drugs" across all stages of the supply chain [1] Group 2: Responsibilities of Pharmacies - Pharmacies, as drug operating enterprises, have the responsibility to strictly verify the sources of the drugs they purchase [1] - The NHSA calls on designated medical institutions to not only request invoices during procurement but also to use the NHSA's app to confirm whether the drugs have been settled through medical insurance funds, ensuring they do not accept or trade "returned drugs" [1]